Anavex Life Sciences Past Earnings Performance
Past criteria checks 0/6
Anavex Life Sciences's earnings have been declining at an average annual rate of -14.4%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
-14.4%
Earnings growth rate
-3.7%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | -32.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Anavex Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -42 | 11 | 38 |
| 31 Mar 24 | 0 | -41 | 11 | 36 |
| 31 Dec 23 | 0 | -43 | 11 | 38 |
| 30 Sep 23 | 0 | -48 | 12 | 41 |
| 30 Jun 23 | 0 | -52 | 13 | 42 |
| 31 Mar 23 | 0 | -53 | 13 | 41 |
| 31 Dec 22 | 0 | -50 | 13 | 38 |
| 30 Sep 22 | 0 | -48 | 13 | 35 |
| 30 Jun 22 | 0 | -45 | 12 | 32 |
| 31 Mar 22 | 0 | -43 | 11 | 32 |
| 31 Dec 21 | 0 | -41 | 11 | 29 |
| 30 Sep 21 | 0 | -38 | 9 | 28 |
| 30 Jun 21 | 0 | -32 | 8 | 24 |
| 31 Mar 21 | 0 | -28 | 7 | 22 |
| 31 Dec 20 | 0 | -28 | 6 | 22 |
| 30 Sep 20 | 0 | -26 | 6 | 21 |
| 30 Jun 20 | 0 | -26 | 6 | 20 |
| 31 Mar 20 | 0 | -26 | 6 | 20 |
| 31 Dec 19 | 0 | -26 | 7 | 20 |
| 30 Sep 19 | 0 | -26 | 7 | 20 |
| 30 Jun 19 | 0 | -26 | 7 | 20 |
| 31 Mar 19 | 0 | -23 | 7 | 16 |
| 31 Dec 18 | 0 | -20 | 7 | 14 |
| 30 Sep 18 | 0 | -17 | 6 | 11 |
| 30 Jun 18 | 0 | -17 | 6 | 11 |
| 31 Mar 18 | 0 | -18 | 6 | 12 |
| 31 Dec 17 | 0 | -14 | 5 | 9 |
| 30 Sep 17 | 0 | -13 | 5 | 9 |
| 30 Jun 17 | 0 | -15 | 7 | 8 |
| 31 Mar 17 | 0 | -13 | 7 | 7 |
| 31 Dec 16 | 0 | -14 | 6 | 8 |
| 30 Sep 16 | 0 | -15 | 8 | 7 |
| 30 Jun 16 | 0 | -14 | 8 | 4 |
| 31 Mar 16 | 0 | -16 | 8 | 4 |
| 31 Dec 15 | 0 | -15 | 8 | 3 |
| 30 Sep 15 | 0 | -12 | 5 | 2 |
| 30 Jun 15 | 0 | -15 | 2 | 2 |
| 31 Mar 15 | 0 | -12 | 2 | 1 |
| 31 Dec 14 | 0 | -11 | 2 | 1 |
| 30 Sep 14 | 0 | -10 | 2 | 1 |
| 30 Jun 14 | 0 | -5 | 3 | 0 |
| 31 Mar 14 | 0 | -4 | 3 | 0 |
Quality Earnings: 12X1 is currently unprofitable.
Growing Profit Margin: 12X1 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 12X1 is unprofitable, and losses have increased over the past 5 years at a rate of 14.4% per year.
Accelerating Growth: Unable to compare 12X1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 12X1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 12X1 has a negative Return on Equity (-32%), as it is currently unprofitable.